Abstract
Despite both enthusiasm and concern regarding data sharing from clinical trials, few studies have documented the outputs of data sharing. The FDA has a considerable collection of raw data from drugs for their marketing authorization. An examination of data sharing with the FDA provides a snapshot into studies that this may facilitate.
Original language | English (US) |
---|---|
Pages (from-to) | 395-399 |
Number of pages | 5 |
Journal | Trends in Cancer |
Volume | 7 |
Issue number | 5 |
DOIs | |
State | Published - May 2021 |
Externally published | Yes |
Keywords
- FDA
- data sharing
- secondary data analysis
ASJC Scopus subject areas
- Oncology
- Cancer Research